These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 23475461)

  • 1. Potential mechanisms for renal damage in beta-thalassemia.
    Mallat NS; Mallat SG; Musallam KM; Taher AT
    J Nephrol; 2013; 26(5):821-8. PubMed ID: 23475461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of renal disease in β-thalassemia.
    Musallam KM; Taher AT
    J Am Soc Nephrol; 2012 Aug; 23(8):1299-302. PubMed ID: 22677552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal complications in transfusion-dependent beta thalassaemia.
    Ponticelli C; Musallam KM; Cianciulli P; Cappellini MD
    Blood Rev; 2010 Nov; 24(6):239-44. PubMed ID: 20850917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
    Economou M; Printza N; Teli A; Tzimouli V; Tsatra I; Papachristou F; Athanassiou-Metaxa M
    Acta Haematol; 2010; 123(3):148-52. PubMed ID: 20185899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective study of tubular dysfunction in pediatric patients with Beta thalassemia major receiving deferasirox.
    Naderi M; Sadeghi-Bojd S; Valeshabad AK; Jahantigh A; Alizadeh S; Dorgalaleh A; Tabibian S; Bamedi T
    Pediatr Hematol Oncol; 2013 Nov; 30(8):748-54. PubMed ID: 24134694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal functions in pediatric patients with beta-thalassemia major: relation to chelation therapy: original prospective study.
    Hamed EA; ElMelegy NT
    Ital J Pediatr; 2010 May; 36():39. PubMed ID: 20500848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia.
    Dee CM; Cheuk DK; Ha SY; Chiang AK; Chan GC
    Br J Haematol; 2014 Nov; 167(3):434-6. PubMed ID: 24989901
    [No Abstract]   [Full Text] [Related]  

  • 8. Morbidities and mortality in transfusion-dependent Beta-thalassemia patients (single-center experience).
    Mokhtar GM; Gadallah M; El Sherif NH; Ali HT
    Pediatr Hematol Oncol; 2013 Mar; 30(2):93-103. PubMed ID: 23301991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired proximal renal tubular dysfunction in β-thalassemia patients treated with deferasirox.
    Yacobovich J; Stark P; Barzilai-Birenbaum S; Krause I; Pazgal I; Yaniv I; Tamary H
    J Pediatr Hematol Oncol; 2010 Oct; 32(7):564-7. PubMed ID: 20733517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of iron overload and glomerular filtration rate estimated by cystatin C in patients with β-thalassemia major.
    Al-Khabori M; Bhandari S; Al-Rasadi K; Mevada S; Al-Dhuhli H; Al-Kemyani N; Daar S
    Hemoglobin; 2014; 38(5):365-8. PubMed ID: 25074643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Documentation of renal glomerular and tubular impairment and glomerular hyperfiltration in multitransfused patients with beta thalassemia.
    Deveci B; Kurtoglu A; Kurtoglu E; Salim O; Toptas T
    Ann Hematol; 2016 Feb; 95(3):375-81. PubMed ID: 26596972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glomerular involvement in adults with sickle cell hemoglobinopathies: Prevalence and clinical correlates of progressive renal failure.
    Guasch A; Navarrete J; Nass K; Zayas CF
    J Am Soc Nephrol; 2006 Aug; 17(8):2228-35. PubMed ID: 16837635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-thalassemia: renal complications and mechanisms: a narrative review.
    Demosthenous C; Vlachaki E; Apostolou C; Eleftheriou P; Kotsiafti A; Vetsiou E; Mandala E; Perifanis V; Sarafidis P
    Hematology; 2019 Dec; 24(1):426-438. PubMed ID: 30947625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron overload in β-thalassemia intermedia: an emerging concern.
    Musallam KM; Cappellini MD; Taher AT
    Curr Opin Hematol; 2013 May; 20(3):187-92. PubMed ID: 23426199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversible Fanconi syndrome in a pediatric patient on deferasirox.
    Rheault MN; Bechtel H; Neglia JP; Kashtan CE
    Pediatr Blood Cancer; 2011 Apr; 56(4):674-6. PubMed ID: 21298760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal abnormalities in sickle-cell beta-thalassemia.
    Elisaf M; Katopodis K; Siamopoulos KC
    Am J Hematol; 2001 Jan; 66(1):68-9. PubMed ID: 11426501
    [No Abstract]   [Full Text] [Related]  

  • 18. Renal tubular dysfunction in pediatric patients with beta-thalassemia major.
    Ahmadzadeh A; Jalali A; Assar S; Khalilian H; Zandian K; Pedram M
    Saudi J Kidney Dis Transpl; 2011 May; 22(3):497-500. PubMed ID: 21566307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications.
    Farmaki K; Tzoumari I; Pappa C
    Blood Cells Mol Dis; 2011 Jun; 47(1):33-40. PubMed ID: 21531154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major.
    Papadopoulos N; Vasiliki A; Aloizos G; Tapinis P; Kikilas A
    Ann Pharmacother; 2010 Jan; 44(1):219-21. PubMed ID: 19934389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.